癌症中的蛋白质体功能障碍:机械途径和向疗法
Pranit Hemant Bagde1, Meenakshi Kandpal1, Annu Rani1
1Infection Bioengineering Group, Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Madhya Pradesh, India.
Journal of cellular biochemistry
|January 31, 2025
概括
无素-蛋白酶体系统 (UPS) 降解蛋白质,其功能障碍与癌症有关. 准26S蛋白酶组复合体为开发新型癌症疗法提供了一个有希望的策略.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 细胞生物学 细胞生物学
背景情况:
- 蛋白质体是关键的真核生物复合体,通过无处不在调节蛋白质命运.
- 蛋白质酶功能障碍与癌症,神经退行性疾病和衰老有关.
- 癌细胞表现出较高的蛋白质循环和平衡要求,严重依赖UPS.
研究的目的:
- 为了研究26S蛋白酶体复合体在癌症发生过程中在全方位蛋白酶体系统 (UPS) 中的作用.
- 通过了解UPS在癌症发展中的参与来确定癌症治疗的潜在治疗点.
主要方法:
- 审查关于蛋白酶体功能和癌症生物学现有文献.
- 分析了在癌细胞增殖和存活中无素-蛋白酶体系统的作用.
- 探索26S蛋白酶组合体作为治疗点.
主要成果:
- UPS对于癌细胞的快速增殖和对亡的抗性至关重要.
- 癌细胞特别依赖蛋白质酶体活动来生存.
- 26S蛋白酶组复合体是癌症中UPS的关键组成部分.
结论:
- 无素-蛋白酶体系统在癌症进展中起着至关重要的作用.
- 准26S蛋白酶组合体是开发有效抗癌疗法的可行策略.
- 对UPS抑制剂的进一步研究对癌症治疗具有重大前景.
相关概念视频
The Proteasome
803
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
803
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
The Proteasome Structure
681
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
681
Regulated Protein Degradation
2.5K
2.5K


